Warning! Javascript is disabled. Please enable javascript for a completly functioning application.

2013
Eli Lilly v. Canada Eli Lilly and Company v. Canada (ICSID Case No. UNCT/14/2)
Applicable IIA
Nationality of the parties
Canada
United States of America
Summary of matters at issue
Patents for two pharmaceutical products, Strattera and Zyprexa.
Claims arising out of the invalidation of the claimant's Strattera and Zyprexa pharmaceutical patents by Canada.
Economic sector and subsector
Secondary: C - Manufacturing
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Arbitral rules and administering institution
UNCITRAL
ICSID (International Centre for Settlement of Investment Disputes)
Composition of tribunal
van den Berg, A. J.
Born, G. B.
Bethlehem, D.
Status/Outcome of original proceedings
Decided in favour of State
Decisions rendered
Amount of compensation
500.00 mln CAD (483.40 mln USD)
Data not available
IIA breaches alleged/found
Indirect expropriation

Fair and equitable treatment/Minimum standard of treatment, including denial of justice claims
None - all claims dismissed at the merits stage
Follow-on proceedings
None
Link to Italaw's case page